Şunu aradınız:: ps (İzlandaca - İngilizce)

acwy- ps
acwy-ps

ps bakendi
ps backend

aldur who ps
age who ps

acwy-ps bóluefni
acwy-ps vaccine

breyta í ps snið 1
convert to ps level 1

*. ps_bar_postscript (*. ps)
*. ps_bar_postscript (*. ps)

p-gildi menveo gegn acwy- ps
p value menveo vs acwy-ps

grunnlínu ecog líkamlegt ástand (ps) = 0
baseline ecog performance status (ps) = 0

acwy-ps hsba ≥1:8 (95% ci)
acwy-ps hsba ≥ 1:8 (95% ci)

einstaklingar bólusettir 30 til 42 mánuðum áður með acwy-ps
subjects vaccinated 30 to 42 months previously with acwy-ps

prenta texta hratt (ekki fyrir ps prentara)
fast text printing (non-ps printers only)

flyt inn ps- skrá sem pdf (þetta gæti teki tíma)...
importing ps file as pdf (this may take a while)...

Örvunarskammtur af menveo var gefinn 5 árum eftir frumbólusetningu með menveo eða acwy-ps.
a booster dose of menveo was administered 5 years after primary vaccination with menveo or acwy-ps.

Í tveimur stuðningsrannsóknum v59p8 og v59p10 var ónæmingargeta menveo borin saman við acwy-ps.
in two supportive studies v59p8 and v59p10 immunogenicity of menveo was compared to acwy-ps.

ldh: laktat dehýdrógenasi, ecog ps: eastern cooperative oncology group performance status
ldh: lactate dehydrogenase, ecog ps: eastern cooperative oncology group performance status

sjúklingar með ecog ps gildi 2 eða hærra voru útilokaðir frá rannsókninni á nýrnafrumukrabbameini (sjá kafla 5.1).
patients with an ecog (eastern cooperative oncology group) performance status of 2 or higher were excluded from the rcc study (see section 5.1).

forritið "ps2pdf" fannst ekki, þannig að okular getur ekki notað það til að flytja inn ps skrár.
the program "ps2pdf" was not found, so okular can not import ps files using it.

eins og við er að búast er tíðni svörunar lægri hjá sjúklingum í lélegu líkamsástandi (performance status, ps > 1) og tíðni fylgikvilla eins og hita, sýkinga og blóðsýkinga hærri (sjá kafla 4.8).
as expected, patients with poor performance status (ps > 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).